Antiviral Drugs in the Prophylaxis of HBV Infection

Author(s): A. Masgala, G. Nikolopoulos, S. Tsiodras, S. Bonovas, N. M. Sitaras

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 35 , 2012

Become EABM
Become Reviewer
Call for Editor


Reactivation of hepatitis B infection (HBV) is known to occur in liver graft recipients and in chronic carriers of the surface antigen of HBV who receive immunosuppressive therapy. The use of hepatitis B immune globulin alone or in combination with antiviral agents such as lamivudine, adefovir, tenofovir, entecavir, famciclovir, ganciclovir, as prophylaxis in HBV liver transplants, has been well documented. In terms of HBV positive carriers undergoing cytotoxic chemotherapy, the preemptive use of nucleoside or nucleotide analogues seems to be effective. Monotherapy or combination of antiviral drugs, as well as the optimal duration of HBV prophylaxis, is to be determined.

Keywords: Antiviral drugs, HBV infection, immunosuppression, nucleos(t)ide analogues, prophylaxis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 29 November, 2012
Page: [5940 - 5946]
Pages: 7
DOI: 10.2174/0929867311209065940
Price: $65

Article Metrics

PDF: 13